Literature DB >> 29133593

Adipose-Derived VEGF-mTOR Signaling Promotes Endometrial Hyperplasia and Cancer: Implications for Obese Women.

Subhransu S Sahoo1,2, Janine M Lombard3, Yvette Ius4, Rachel O'Sullivan4, Lisa G Wood2, Pravin Nahar5, Kenneth Jaaback4, Pradeep S Tanwar6,2,7,8.   

Abstract

Obesity is responsible for increased morbidity and mortality in endometrial cancer. Despite the positive correlation of body mass index (BMI) or obesity in endometrial carcinogenesis, the contribution of adipose tissue to the pathogenesis of endometrial hyperplasia and cancer is unclear. This study clarifies the role of adipocytes in the pathogenesis of endometrial cancer by demonstrating that adipocyte-conditioned medium (ACM) increases proliferation, migration, and survival of endometrial cancer cells compared with preadipocyte-conditioned medium (PACM). Comparative cytokine array analysis of ACM and PACM reveal upregulation of a group of cytokines belonging to the VEGF signaling pathway in ACM. VEGF protein expression is upregulated in visceral adipose tissue (VAT) in obese patients, which is correlated with increased tumor growth in an in vivo xenograft model. The increased tumor size is mechanistically associated with the activation of the PI3K/AKT/mTOR pathway, a downstream target of VEGF signaling, and its suppression decreased the growth-promoting effects of VAT on endometrial cancer cells. Similar to the human model systems, pathologic changes in endometrial cells in a hyperphagic obese mouse model are associated with increased body weight and hyperactive mTOR signaling. Analysis of human tissue specimens depicts increased in tumor vasculature and VEGF-mTOR activity in obese endometrial cancer patients compared with nonobese patients. Collectively, these results provide evidence that VEGF-mTOR signaling drives endometrial cell growth leading to hyperplasia and cancer.Implications: Adipocyte-derived VEGF-mTOR signaling may be an attractive therapeutic target against endometrial cancer in obese women. Mol Cancer Res; 16(2); 309-21. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29133593     DOI: 10.1158/1541-7786.MCR-17-0466

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  14 in total

Review 1.  Linking obesity-induced leptin-signaling pathways to common endocrine-related cancers in women.

Authors:  Eunice Nyasani; Iqbal Munir; Mia Perez; Kimberly Payne; Salma Khan
Journal:  Endocrine       Date:  2018-09-14       Impact factor: 3.633

2.  Gene expression changes and promoter methylation with the combined effects of estradiol and leptin in uterine tissue of the ovariectomized mice model of menopause.

Authors:  Abhishek Shetty; Thejaswini Venkatesh; Rie Tsutsumi; Padmanaban S Suresh
Journal:  Mol Biol Rep       Date:  2019-10-10       Impact factor: 2.316

3.  Preclinical Efficacy and Involvement of AKT, mTOR, and ERK Kinases in the Mechanism of Sulforaphane against Endometrial Cancer.

Authors:  Rajani Rai; Kathleen Gong Essel; Doris Mangiaracina Benbrook; Justin Garland; Yan Daniel Zhao; Vishal Chandra
Journal:  Cancers (Basel)       Date:  2020-05-18       Impact factor: 6.639

4.  Expression profiles of VEGF-A, VEGF-D and VEGFR1 are higher in distant metastases than in matched primary high grade epithelial ovarian cancer.

Authors:  Minna Sopo; Maarit Anttila; Kirsi Hämäläinen; Annukka Kivelä; Seppo Ylä-Herttuala; Veli-Matti Kosma; Leea Keski-Nisula; Hanna Sallinen
Journal:  BMC Cancer       Date:  2019-06-14       Impact factor: 4.430

5.  Targeting Endometrial Cancer Stem Cell Activity with Metformin Is Inhibited by Patient-Derived Adipocyte-Secreted Factors.

Authors:  Sarah J Kitson; Matthew Rosser; Deborah P Fischer; Kay M Marshall; Robert B Clarke; Emma J Crosbie
Journal:  Cancers (Basel)       Date:  2019-05-11       Impact factor: 6.639

Review 6.  The Role of Metabolic Syndrome in Endometrial Cancer: A Review.

Authors:  Xiao Yang; Jianliu Wang
Journal:  Front Oncol       Date:  2019-08-08       Impact factor: 6.244

Review 7.  Targeting obesity-related dysfunction in hormonally driven cancers.

Authors:  Maria M Rubinstein; Kristy A Brown; Neil M Iyengar
Journal:  Br J Cancer       Date:  2021-04-28       Impact factor: 7.640

Review 8.  The Emerging Role of the Microenvironment in Endometrial Cancer.

Authors:  Subhransu S Sahoo; Xu Dong Zhang; Hubert Hondermarck; Pradeep S Tanwar
Journal:  Cancers (Basel)       Date:  2018-10-30       Impact factor: 6.639

9.  VEGF-mTOR signaling links obesity and endometrial cancer.

Authors:  Subhransu S Sahoo; Pradeep S Tanwar
Journal:  Oncoscience       Date:  2018-06-27

10.  PAI-1-Dependent Inactivation of SMAD4-Modulated Junction and Adhesion Complex in Obese Endometrial Cancer.

Authors:  Li-Ling Lin; Edward R Kost; Chun-Lin Lin; Philip Valente; Chiou-Miin Wang; Mikhail G Kolonin; Alexes C Daquinag; Xi Tan; Nicholas Lucio; Chia-Nung Hung; Chen-Pin Wang; Nameer B Kirma; Tim H-M Huang
Journal:  Cell Rep       Date:  2020-10-13       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.